ReNeuron Group plc (LON:RENE – Get Free Report)’s stock price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of GBX 3.38 ($0.04) and traded as low as GBX 3.28 ($0.04). ReNeuron Group shares last traded at GBX 3.38 ($0.04), with a volume of 177,373 shares trading hands.
ReNeuron Group Price Performance
The company has a quick ratio of 2.02, a current ratio of 1.51 and a debt-to-equity ratio of 14.25. The company has a fifty day simple moving average of GBX 3.38 and a 200 day simple moving average of GBX 3.38. The firm has a market capitalization of £1.93 million, a P/E ratio of -37.50 and a beta of 0.83.
About ReNeuron Group
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease.
Further Reading
- Five stocks we like better than ReNeuron Group
- The Significance of Brokerage Rankings in Stock Selection
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- Stock Sentiment Analysis: How it Works
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- What is a Low P/E Ratio and What Does it Tell Investors?
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for ReNeuron Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ReNeuron Group and related companies with MarketBeat.com's FREE daily email newsletter.
